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Ataxia-ocular apraxia 2 (AOA2) was recently identified as a new
autosomal recessive ataxia. We have now identified causative
mutations in 15 families, which allows us to clinically define
this entity by onset between 10 and 22 years, cerebellar
atrophy, axonal sensorimotor neuropathy, oculomotor apraxia
and elevated alpha-fetoprotein (AFP). Ten of the fifteen
mutations cause premature termination of a large DEAxQ-box
helicase, the human ortholog of yeast Sen1p, involved in RNA
maturation and termination.
We previously identified a 16-cM interval on chromosome 9q34 associ-
ated with an autosomal recessive adolescent-onset cerebellar ataxia seg-
regating in two families1,2, one with additional oculomotor apraxia1 and
the second with associated elevated serum AFP, immunoglobulins and
creatine kinase levels but no oculomotor apraxia2,3. We identified nine
additional families with ataxia linked to 9q34 by homozygosity mapping
(Supplementary Methods online). As most affected individuals had
both oculomotor apraxia and elevated AFP levels we assumed that they
were affected by the same disorder, which we named AOA2 (OMIM
606002). We identified distal and proximal recombinations in families
with two affected individuals (Fig. 1a), localizing the defective gene
underlying AOA2 to a 1.1-Mb interval containing 13 genes (Fig. 1b) and
three groups of overlapping spliced expressed-sequence tags, which we
analyzed for nucleotide changes but found no mutations. We also found
that the unspliced mRNA AK024331 overlaps with the KIAA0625 cDNA
and is part of a larger transcript overlapping with additional exons on
the 5′ side. We obtained an open reading frame of 8,031 nucleotides and
24 exons (Fig. 1c), of which exon 8 was 4,177 nucleotides long. We con-
firmed the prediction and size of the transcript by long-range RT-PCR
experiments spanning the putative exon 1 and 3′ untranslated region in
human fibroblast and lymphoblastoid cell lines (data not shown) and by
hybridization of a human northern blot with a probe spanning putative
exons 8–24 (Fig. 1d). We also identified an alternative transcript that is
2.4 kb longer, resulting from a second polyadenylation site (human
mRNAs AB014525 and AK022902; Fig. 1d).
We sequenced exons 1–18 and flanking intronic sequences in fami-
lies with ataxia linked to this region and in additional individuals with
either AOA or ataxia with elevated AFP levels and found 15 different
disease-associated mutations in 15 families (Table 1). Ten of these
mutations, including mutations in the two families in whom we first
identified AOA2, cause truncation of the protein, indicating that this is
the gene underlying AOA2. We found the nonsense mutation R1363X
in three unrelated families originating from Portugal, Cabo Verde
(once a Portuguese colony) and Spain, suggestive of an Iberian founder
event, although recurrent C→T changes on this CpG dinucleotide can-
not be formally excluded. Absence of the five missense mutations in 150
unrelated and unaffected individuals sharing the same ethnic origin as
the affected individuals indicates that they are not frequent polymor-
phisms. Two of the missense mutations were associated with a
frameshift mutation inherited from the other parent, and the remain-
ing missense mutations were present in the homozygous state in the
affected individuals. We identified four variants resulting in amino acid
changes and a silent nucleotide change (Table 1) on the normal chro-
mosome of healthy siblings or parents from several families, indicating
that they were frequent polymorphisms.
Before our mapping, the disorders in the different families were con-
sidered to be clinically distinct entities. We can now delineate the com-
mon clinical phenotype associated with mutant senataxin, illustrating
the power of defining disorders by their genetic locus and identified
mutations. We considered only those families in whom we had con-
firmed mutations when delineating the AOA2 phenotype, as some con-
sanguineous families with sporadic affected individuals could show
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homozygosity at 9q34 by chance rather than by linkage. AOA2 shares
several clinical features with AOA1, including gait ataxia, cerebellar atro-
phy, sensory-motor neuropathy (93%) and oculomotor apraxia (47%),
but can be distinguished by a later onset (at 10–22 years of age in AOA2
versus 2–15 years of age in AOA1), high levels of AFP (86%, although
normal laboratory values are highly variable; Supplementary Table 1
online) and normal serum albumin levels after a long disease duration.
Other features were more variable, including choreoathetosis, dystonic
movements and elevated serum levels of creatine kinase. Some features
of the core clinical phenotype for AOA2 are also seen in ataxia-telangiec-
tasia and ataxia-telangiectasia–like disorder4,5. Because individuals with
the latter conditions are predisposed to solid tumors, protein-based
assays to distinguish between AOA2 and ataxia-telangiectasia and
ataxia-telangiectasia–like disorder are needed.
The predicted protein encoded by the gene mutated in AOA2 is 2,677
amino acids long and contains at its C terminus a classical seven-motif
domain found in the superfamily 1 of helicases6. In particular, it shares
extensive homologies with the fungal Sen1p proteins (Fig. 1e), and so
we named it senataxin (SETX). Saccharomyces
cerevisiae Sen1p is involved in splicing and ter-
mination of tRNA, small nuclear RNA and
small nucleolar RNA and has RNA helicase
activity encoded by its C-terminal domain7–9.
Schizosaccharomyces pombe has two Sen1
genes. The first reported S. pombe Sen1p
(Sen1p1, encoded on chromosome I) has both
RNA and DNA helicase activities9. Of all the
fungal Sen1p proteins, however, the second 
S. pombe Sen1p (Sen1p2, encoded on chromo-
some II) has the highest homology with sen-
ataxin over the N-terminal domain (20%
identity over 466 residues). The C-terminal
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Figure 1 Genetic and transcriptional analysis of
the AOA2 region. (a) 9q34 haplotype segregation
in families P13 and Tun4. Markers are indicated
on the left of each genealogical tree, in order from
centromere to telomere. Distances in cM are
indicated. Regions of homozygosity are boxed.
Individual II.2 of family Tun4 was normal on
neurological examination at 33 years of age, well
beyond the age of onset for her affected brother
and sister (21 years). (b) Transcriptional map of
the critical region associated with AOA2. The
KIAA0625 cDNA and AK024331 mRNA are part
of SETX. (c) Exon organization of SETX. Exons
(boxes) and small introns (lines) are represented 
to scale. Introns above 1 kb or 7 kb in length are
interrupted with a slash or an X, respectively. 
(d) Human multiple tissue northern blot (Clontech)
analysis. Tissues are indicated above each lane.
RNA from the brain and liver lanes was partially
degraded. Autoradiography of the skeletal muscle
lane from the same experiment after 24 h is also
shown, to allow resolution of the two isoforms.
Autoradiography exposure time is indicated below.
(e) Semiquantitative RT-PCR analysis of adult and
fetal (embryonic day (E) 13.5) tissues for mouse
Setx and Hprt transcripts. Setx is ubiquitously
expressed. Hprt transcript analysis of the same
reverse transcription samples serves as a control
for the amount of analyzed tissue. (f) Domain
organization of senataxin (SETX) and related
proteins. The N-terminal domain shared between
the SETX and Sen1 proteins is indicated in
orange. The helicase domain is indicated in green.
The position of the seven helicase motifs (I–VI) is
indicated on top. The intermediate domain (white)
is weakly conserved between mammalian SETX
and fungal Sen1 proteins. Domains specific to the
RENT1 or to the IGHMBP2 proteins have a
distinct color code. HS, Homo sapiens; SP, S.
pombe. Total amino acid (aa) length is indicated
below the protein boxes.
I.1 I.2
14
6
2
6
5
3
14
5
6
3
12
2
4
5
4
14
5
6
6
5
3
14
5
6
3
12
2
4
5
10
14
2
2
6
5
3
14
5
6
3
12
2
4
5
4
12
6
5
1
12
4
2
7
4
3
9
7
8
5
4
II.1
14
6
2
6
5
3
14
5
6
3
12
2
4
5
4
14
2
2
6
5
3
14
5
6
3
9
7
8
5
4
14
6
2
6
5
3
14
5
6
3
12
2
4
5
4
12
6
5
1
12
4
2
7
4
3
9
7
8
5
4
14
6
2
6
5
3
14
5
6
3
12
2
4
5
4
14
2
2
6
5
3
14
5
6
3
12
2
4
5
4
II.2
14
5
6
6
5
3
14
5
6
3
12
2
4
5
10
12
6
5
1
12
4
2
7
4
3
9
7
8
5
4
II.3
14
5
6
6
5
3
14
5
6
3
12
2
4
5
10
14
2
2
6
5
3
14
5
6
3
12
2
4
5
4
II.4 II.5
Family P13
II.2II.1
I.2I.1
II.3 II.4 II.6II.52
Family Tun4
1
3
3
1
11
10
2
4
4
3
16
6
1
4
9
1
7
5
2
3
4
8
8
5
1
4
9
1
7
5
2
3
nt
8
8
5
1
4
9
1
11
4
2
1
nt
4
15
5
D9S290
D9S260
D9S1795
D9S159
D9S1831
D9S1863
D9S179
D9S1847
D9S1830
STR11
STR3
D9S1793
D9S1818
D9S1826
D9S158
cM
0
2
0
1
1
1
0
1
3
3
7
3
D9S290
D9S260
D9S1795
D9S159
D9S1831
D9S1863
D9S179
D9S1847
D9S1830
STR11
STR3
D9S1793
D9S1818
D9S1826
D9S158
cM
0
2
0
1
1
1
0
1
3
3
7
3
STR32
STR33
STR34
STR35
STR36
D9S179
STR37
D9S1847
D9S1830
STR38
STR3
D9S1793
STR32
STR33
STR34
STR35
STR36
D9S179
STR37
D9S1847
D9S1830
STR38
STR3
D9S1793
cM
1
3
1
1
3
3
1
11
10
2
4
4
3
16
6
1
4
9
1
11
4
2
1
4
4
15
5
1
3
3
1
11
10
2
4
nt
3
16
6
1
3
3
1
11
10
2
1
nt
4
15
5
1
3
3
1
11
10
2
4
4
3
16
6
1
3
3
1
11
10
2
4
4
3
16
6
1
3
3
1
11
10
2
4
4
3
16
6
1
3
3
1
11
10
2
4
4
3
16
6
1
4
9
1
7
5
2
3
nt
8
8
5
1
4
9
1
11
4
2
1
nt
4
15
5
cM
1
3
1
a
5'3'
1 kb
TAG ATG
1234567
100 kbW
TN
G
2
K
IA
A
06
25
TT
F1
B
A
R
H
L1
D
D
X
31
G
TF
3C
4
FL
J3
27
04
C
9o
rf9
TS
C
1
G
FI
1B
G
TF
3C
5
C
EL
R
A
LG
D
S
FSA
K
02
43
31
8910
XX
111213
X
1415161718192021222324c
b
D
9S
17
9
ST
R
3
AOA2 interval
He
art
Br
ain
 (w
hol
e)
Pla
ce
nta
Lu
ng
Liv
er
Sk
ele
tal
 m
us
cle
Kid
ne
y
Sk
ele
tal
 m
us
cle
9 kb
11.4 kb 9 kb11.4 kb
SETX: 14 d 24 h
He
art
 
(ad
ult
)
He
art
 (E
13
.5)
Liv
er
 (ad
ult
)
Liv
er
 (E
13.
5)
Sp
lee
n (a
du
lt)
Lu
ng
 (ad
ult
)
Sk
ele
tal
 m
us
cle
 (ad
ult
)
Sk
ele
tal
 m
us
cle
 (E
13.
5)
Pa
nc
re
as
 (ad
ult)
Br
ain
 st
em
 (ad
ult)
Br
ain
 s
tem
 (ad
ult
)
Sp
ina
l c
ord
 (ad
ult)
Ce
reb
ell
um
 (ad
ult)
W
ho
le 
bra
in 
(ad
ult)
W
ho
le 
bra
in 
(E1
3.5
)
Setx
Hprt
480 bp
400 bp
d e
HS SETX
SP Sen1-2
HS RENT1 
HS IGHMBP2
I IIIa III IV VVI
I IIIa III IV VVI
I IIIa III IV V VI
I IIIa III IV V VI
2,677 aa
1,944 aa
1,118 aa
993 aa
f
©
20
04
 N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
u
p 
 
ht
tp
://
w
w
w.
n
at
ur
e.
co
m
/n
at
ur
eg
en
et
ic
s
B R I E F  C O M M U N I C AT I O N S
NATURE GENETICS VOLUME 36 | NUMBER 3 | MARCH 2004 227
domain of senataxin and the Sen1p proteins shares significant similarity
with two other members of the DExxQ-box family of helicases (Fig. 1f):
RENT1/Upf1, involved in nonsense mediated RNA decay10, and
IGHMBP2, defective in spinal muscular atrophy with respiratory dis-
tress11 (OMIM 604320), a human disorder of motor neurons, and in
mouse neuromuscular degeneration12. Upf1 proteins have RNA helicase
activity, but IGHMBP2 was initially identified as a DNA binding protein
with transcriptional transactivating properties13. It is therefore possible
that, like S. pombe Sen1p1, senataxin has both RNA and DNA helicase
activities and that senataxin acts in a DNA repair pathway, like several
other proteins defective in autosomal recessive cerebellar ataxias, as in
ataxia-telangiectasia4, AOA1 (ref. 14), ataxia-telangiectasia–like disor-
der5 and spinocerebellar ataxia with peripheral neuropathy 1 (ref. 15).
Alternatively, the results also suggest that senataxin might be a nuclear
RNA helicase with a role in the splicing machinery and that the molecu-
lar pathology of AOA2 may share features with spinal muscular atrophy
and spinal muscular atrophy with respiratory distress. Our results add to
the increasing evidence to suggest that both DNA repair and RNA splic-
ing are key factors in several neurodegenerative disorders, including the
newly identified AOA2, and further work may elucidate the role of these
mechanisms in neuronal integrity and neurodegeneration.
GenBank accession numbers. Human SETX, AY362728; mouse Setx,
BK001523. Human cDNA and mRNAs: KIAA0625, NM_015046, 31543019;
AK024331, 10436690; AK022902, 10434561; AB014525, 3327063. Mouse
mRNAs: AK044730, 26336742; AK048354, 26339275. Human expressed-
sequence tags: BC032622, 22749753; CB162163, 28148289; AA578438,
2356622; AW812833, 7905827; AI216401, 3785442. Mouse expressed-sequence
tags: BU503417, 22809650; BY718091, 27131208. Sen1 proteins: Neurospora
crassa, AL442164, 16945408; S. pombe (Sen1p2), NC_003423, 19112847.
Note: Supplementary information is available on the Nature Genetics website.
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Table 1  Mutations and polymorphisms in SETX
Family (geographic origin) Nucleotide change (exon) Amino acid change Mutation status
Mutations
Alg5 (Algeria) 2602C→T (8) Q868X Homozygous
Alg11 (Algeria) 915G→T (6) W305C Homozygous
Can7 (Canada) 5070insT (8) fs after I1690 Homozygous
F30 (Vietnam) 2622–2625delAGTT (8) fs after L874 Homozygous
F77 (France) 994C→T (6) R332W Compound
2966–2970delGGAAA (8) fs after Q988 Heterozygous
F88 (France) 5264delC (8) fs after N1754 Heterozygous
P13 (Cabo Verde), F93 (Portugal) and G10 (Spain) 4087C→T (8) R1363X Homozygous
F98 (Turkey) 5249insT (8) fs after L1750 Homozygous
J7 (Japan) 4321C→T (8) Q1441X Homozygous
J8 (Japan) 6638C→T (18) P2213L Homozygous
Pak1 (Pakistan) 2332C→T (8) R788X Homozygous
Tun4 (Tunisia) 1238C→T (8) P413L Homozygous
UK1 (United Kingdom) 879delT (6) fsC292 Compound
5267T→C (8) F1756S Heterozygous
Polymorphisms
F89, J10, Tur1 3147C→T (8) H1049H Homozygous
F88, F89, F90, F91, G10, J8, J10, P13, Tun4, Tur1 3455G→T (8) C1152F Homozygous
F90, F91, G10, P13, Tun4 3576T→G (8) D1192E Homozygous
F88, F90, F91, G10, P13, Tun4 3754G→A (8) G1252R Homozygous
Alg5, F11, F77, F89, F91, F102, J7, J8, J10, Pak1, P13, Tur1, UK1 4156G→A (8) V1386I Homozygous
fs, frameshift.
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